LBRX (LBRX) reported G&A of $7.46M in Q1 2026.

How has LBRX's G&A changed year-over-year?

LBRX's G&A increased by 148.0% year-over-year, from $3.01M to $7.46M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

LBRX LBRX G&A

G&A at other companies

MapLight Therapeutics, Inc. MPLT

$10.82M+188%

Alto NeuroscienceANRO

$6.84M+20.0%

Septerna, Inc.SEPN

$10.29M+50.0%

Xenon PharmaceuticalsXENE

$23.82M+25.1%

Praxis Precision Medicines, Inc.PRAX

$27.87M+100%

Denali Therapeutics Inc.DNLI

$33.51M+14.2%

Other financials

Income statement

See full

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

See full

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

See full

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

See full

Market cap$874.06M+159%

Enterprise value$556.86M—

Returns & leverage

See full

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LBRX's G&A?: LBRX (LBRX) reported G&A of $7.46M in Q1 2026.
How has LBRX's G&A changed year-over-year?: LBRX's G&A increased by 148.0% year-over-year, from $3.01M to $7.46M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.